Doctors from Tata Memorial Hospital, Mumbai, and the Advanced Centre for Training, Research and Education in Cancer (ACTREC), Navi Mumbai, collaborated with IDRS Labs, Bangalore, to develop the first and only oral suspension of 6-mercaptopurine (6-MP) in India.<br />''   <br />''6-MP is a chemotherapy drug used in the treatment of Acute Lymphoblastic Leukemia (ALL), the most common type of blood cancer afflicting children. The child-friendly formulation is available in the form of a powder for Oral Suspension, and is marketed under the tradename PREVALL.<br />'' <br />''<span style="color: #222222;">Dr. Girish Chinnaswamy, Professor & Head, Department of Paediatric Oncology, Tata Memorial Hospital, commented that children with curable cancers such as ALL deserve the best possible care, and formulations such as PREVALL would help in ensuring dose optimization, improving adherence, and maximizing the efficacy of drugs. Dr. Banavali, Director-Academics, Tata Memorial Centre, Mumbai, and a senior paediatric hemato-oncologist commented that the introduction of PREVALL addresses several challenges posed by the current tablet formulation in terms of dosage accuracy, flexibility, and tolerability. </span><br />